OliX Pharmaceuticals, Inc.
Clinical-stage company developing RNAi therapeutics for dermal and ophthalmic diseases.
226950 | KO
Overview
Corporate Details
- ISIN(s):
- KR7226950004
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 고등동 608-3 -, 성남시
- Website:
- https://olixpharma.com
- Sector:
- Manufacturing
Description
OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-20 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 61.6 KB | ||
| 2023-12-20 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정)(OLX75016(비알코올성지방간염 치료제)의 호주 제1상 임상시험 계획 승인)
|
Korean | 14.3 KB | ||
| 2023-12-18 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 227.8 KB | ||
| 2023-12-15 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 10.9 KB | ||
| 2023-12-15 00:00 |
증권발행결과(자율공시)
|
Korean | 5.6 KB | ||
| 2023-12-14 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 10.5 KB | ||
| 2023-12-13 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.2 KB | ||
| 2023-12-07 00:00 |
투자판단관련주요경영사항(GalNAc-asiRNA 기술을 이용한 Collaboration and License Agreement 관련 마일스톤 …
|
Korean | 9.1 KB | ||
| 2023-12-07 00:00 |
주요사항보고서(전환사채권발행결정)
|
Korean | 43.4 KB | ||
| 2023-11-30 00:00 |
기타경영사항(자율공시)(제1회차 전환우선주 전환가액 조정)
|
Korean | 8.8 KB | ||
| 2023-11-30 00:00 |
기타경영사항(자율공시)(제2회차 전환우선주 전환가액 조정)
|
Korean | 8.8 KB | ||
| 2023-11-27 00:00 |
투자판단관련주요경영사항(OLX301A 마일스톤 수령)
|
Korean | 9.5 KB | ||
| 2023-11-23 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.6 KB | ||
| 2023-11-23 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 148.8 KB | ||
| 2023-11-13 00:00 |
분기보고서 (2023.09)
|
Korean | 1.3 MB |
Automate Your Workflow. Get a real-time feed of all OliX Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OliX Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OliX Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
